IT Brief India - Technology news for CIOs & IT decision-makers
India
US court dismisses Natsoft patent claims against Hexaware

US court dismisses Natsoft patent claims against Hexaware

Thu, 18th Jun 2026 (Today)
Sofiah Nichole Salivio
SOFIAH NICHOLE SALIVIO News Editor

A US federal court has dismissed Natsoft's patent claims against Hexaware, covering all claims brought by Natsoft and Updraft against Hexaware and its US subsidiary.

The US District Court for the Northern District of Illinois dismissed patent infringement allegations involving nine patents across two patent families. It also dismissed related state-law claims after declining to retain jurisdiction once the federal patent claims were thrown out.

At the centre of the decision was the court's view that the patents asserted by Natsoft were based on broad, abstract ideas rather than specific inventions. On that basis, the court found them ineligible for protection under US law.

The case was brought against Hexaware and its US subsidiary, Hexaware Technologies Inc. The complaint targeted Amaze, Tensai and RapidX, three platforms developed by the company.

The court has given the plaintiffs time to file an amended complaint adding a new federal claim. If they do not, final judgment is expected to follow.

Patent dispute

The decision addresses the validity and breadth of the patents asserted by Natsoft, not whether Hexaware copied the underlying ideas. Hexaware said its products were developed through internal research and development and that it holds US patents covering methods used in its Amaze and Tensai platforms.

Hexaware also said an additional US patent related to Tensai has been allowed and is expected to issue. It cited this as part of its broader argument that the products named in the case were built through its own engineering work.

Natsoft's claims covered nine patents across two patent families, making the case a broad challenge to several parts of Hexaware's software portfolio. The dismissal removes those patent claims in full at this stage.

Hexaware filed its motion to dismiss in December 2025 and said at the time that it expected the lawsuit to fail.

Srikrishna Ramakarthikeyan commented on the ruling after the decision. "We have been clear about our confidence since the day this suit was filed, and the Court's decision reflects why we held it," said Srikrishna Ramakarthikeyan, Executive Director & CEO of Hexaware.

"These platforms came from our own research and from years of investment by our own engineers. The Court found that what Natsoft asserted was too abstract to be a patentable invention-and Hexaware holds patents of its own precisely because our work is specific, real, and original. Our clients trusted us through this process, and we will keep earning that trust. If this case continues in any form, our response will be the same."

Business impact

Hexaware said the litigation had not materially affected its operations, customer work, partner programmes or financial position. It also said it did not expect disruption if the matter continues in another form.

That point is likely to matter for clients using the platforms named in the lawsuit, particularly because the case involved products within Hexaware's automation and software offering. By saying there had been no operational or financial effect, Hexaware sought to draw a line between the legal dispute and day-to-day business.

The ruling also reflects how US courts continue to assess software-related patents by asking whether claims describe a concrete invention or an abstract idea. In this case, the court concluded that the patents asserted by Natsoft fell on the wrong side of that divide.

For Hexaware, the immediate outcome is the removal of all claims currently before the court, though the window for an amended complaint means the dispute may not yet be over. If the plaintiffs do not add a new federal claim, the court is expected to enter final judgment.

The lawsuit alleged infringement across a broad group of patents, but the court found that the asserted patents claimed abstract ideas rather than specific inventions.